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Abstract
Due to the relationship between biology and culture, we believe that depression, understood as a cultural and
existential phenomenon, has clear markers in molecular biology. We begin from an existential analysis of
depression constituting the human condition and then shift to analysis of biological data confirming, according to
our judgment, its original (ontological) structure. In this way philosophy is involved at the anthropological level, in
as much as it detects the underlying meanings of depression in the original biological-cultural horizon of human
life. Considering the integration of knowledge it is the task of molecular biology to identify the aforementioned
markers, to which the existential aspects of depression are linked to. In particular, recent works show the existence
of a link between serotonin and osteoporosis as a result of a modified expression of the low-density lipoprotein
receptor-related protein 5 gene. Moreover, it is believed that the hereditary or acquired involvement of tryptophan
hydroxylase 2 (Tph2) or 5-hydroxytryptamine transporter (5-HTT) is responsible for the reduced concentration of
serotonin in the central nervous system, causing depression and affective disorders. This work studies the
depression-osteoporosis relationship, with the aim of focusing on depressive disorders that concern the
quantitative dynamic of platelet membrane viscosity and interactome cytoskeleton modifications (in particular
Tubulin and Gsa protein) as a possible condition of the involvement of the serotonin axis (gut, brain and platelet),
not only in depression but also in connection with osteoporosis.
Depression and existential analysis
Memory is not a place of filing and storage of data geo-
graphically placed in our brain, because the brain is not
merely a ‘bundle of neurons’ vivisected in a laboratory.
It is in fact the ‘condition of possibility’ of an integral
being, of an organism having continuously interacting
levels: from the most elementary conatus sese conser-
vandi to the feeling of life [1].
The conscience, as individual expression, full of phe-
nomena and meaning, originating from its biological
roots, considers memory as the most authentic figure of
life and death, or rather the original picture of tragedy
that has always lived in us.
‘Consider the cattle, grazing as they pass you by. They
do not know what is meant by yesterday or today, they
leap about, eat, rest, digest, leap about again, and so
from morn till night and from day to day, fettered to
the moment and its pleasure or displeasure, and thus
neither melancholy nor bored. This is a hard sight for a
man to see; for, though he thinks himself better than
the animals because he is human, he cannot help envy-
ing them their happiness - what they have, a life neither
bored nor painful, is precisely what he wants, yet he
cannot have it because he refuses to be like an animal’.
This powerful consideration by Nietzsche, taken from
one of his most meaningful works On the Use and Abuse
of History for Life [2], recalls that tragedy is the element
that marks unequivocally our life in the world, together
with memory that obsessively reminds man how his
openness to things is characterised by a completeness
and a happiness that, as Jankélévítch said, occurs in the
world as lightning event [3].
In short, happiness appears to us as a transitory event,
almost like a furtive gift of the gods, where pain seems
to live in us as a usual condition. Man is an ill animal,
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as much as he is ‘open to the meaning’ as projects
embodied in the world, and, at the same time, he is
inevitably struck by pain and, above all, by death, that is
the implosion of every meaning.
Memory, shifting from the extended to the identity
level, takes the shape of ‘nostalgia for the centre’; that is,
the lost Unit (that is to say the Principle from which
humans originate) that from a cultural point of view can
be found in the history of religions and in general in the
human thought [4-7]. The ‘nostalgia for the Centre’ is
mainly an erotic archetype, a tormenting desire of love
and beauty, of ontological integrity and harmony,
increasingly fuelled by the melancholy that in Schelling’s
view is a “veil that falls on everything”, things whose
finitude make us worried, anxious.
The question of ontological pain and the precarious-
ness of life ‘here and now’ is absolutely crucial, because
the ‘cosmic silence’ makes us dismayed in the width of
spaces, as well as ‘the silence of the other makes us feel
alone in the small universe of relations’ [8]. So question
on the structural melancholy, paradigmatic expression of
ontological pain, shouldn’t be negletted due to its radical
nature. Infact, even if often remains in the background,
nearly frozen, exorcised, (see Pascal’s Divertissement), it
can never be cancelled, otherwise the deep meaning of
existence will be lost. In this context, memory, through
language, that is to say culture, makes us understand to
what extent depression (ontological or structural, human
pain that embodies the ontic data; that is, to say, the
single historical periods and single biographies) is a mid-
dle ground between the memory of the lost original Prin-
ciple or Centre merely symbolic or religious, and the
unquenchable aspiration for re-integration.
In conclusion, after this existential recognition and in
the light of the biological considerations on depression
herewith developed, we formulated a study hypothesis that
can be expressed as follows: since the biochemical charac-
teristics of the depressed population are the same as those
of the population suffering from scleroderma, and since all
people suffering from scleroderma are depressed, but not
vice versa, is it rational to think that, close to a cultural
origin of depression (the question on human structural
and ontological precariousness herewith examined), there
is a structural biological origin too? In other words, is it
rational to think that depression may be the possible cause
of more serious pathologies (for example, is inflammatory
bowel disease, or osteoporosis, or neuroinflammation a
cause or an effect of depression)?
Depression and biological considerations
Recently, from an experimental basis, the molecular
depression hypothesis [9] and the involvement of interac-
tome [10] have been formulated, as shown in Figures 1
and 2.
It is well known that other assumptions about depres-
sive disorder have exhaustively considered the platelet
membrane as a bridge to psychiatric illness as a result
of changes in viscosity [11]. When membrane viscosity
is very low, due to the increase of arachidonic acid
[12-14], the capacity of platelet and neuronal serotonin
receptors to capture serotonin (5-hydroxytryptamine)
[15] is impaired.
Since we know that serotonin does not cross the
blood-brain barrier, the mechanism described could
explain the strong similarity of the low concentration of
serotonin neurons and platelets in depression [16-19].
In these circumstances, and in the absence of an effi-
cient reuptake mechanism, some serotonin remains free
in the brain neuronal domain, in the enteric neuron
domain and in the circulation.
This can be a strong critical element in the relation-
ship (direct and indirect) that a defect or an excess of
serotonin (as in depression and other psychiatric disor-
ders) can have with serious diseases such as scleroderma
[20], bowel inflammation [21,22], multiple sclerosis [23],
coronary heart disease [24], or osteoporosis [25], where
a high incidence of depressive disorder is documented.
Serotonin-bone connection
Rosen [26], when discussing the connection between
bone, brain and intestine, describes the serotonin cycle
in a detailed and comprehensive way: two different
types of enzymes, tryptophan hydroxylase (Tph)1 and
Tph2 promote the synthesis of serotonin in enterochro-
maffin cells and brain, respectively; serotonin released in
the gut in part stimulates peristalsis and in part enters
the bloodstream, is transported to platelets via the
5-hydroxytryptamine transporter (5HTT), and is stored
or released during the process of coagulation.
In the central nervous system, serotonin, produced
through the action of Tph2, is released at neuronal
synapses. Its reuptake is controlled by the action of
5HTT. Since serotonin does not cross the blood-brain
barrier, all its activity in the brain is mediated by phe-
nomena of synthesis, reuptake and binding to 5HTT
receptors.
This leads us to believe that the only changes in Tph2
or in 5HTT activity, by altering levels of serotonin in
the brain, are the primary cause for the induction of
osteoporotic disease [26]. This mechanism, moreover,
would exclude the involvement of the platelets and their
viscosity, as compared to the skeleton in its integration
with brain and gut.
Analysis of Rosen [26] suggests that, as a result of
lipoprotein receptor-related protein 5 (Lrp5) gene func-
tion loss, there are higher circulating levels of serotonin
and that a deep modification of the 5HTT activity,
adversely affects osteogenesis.
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Figure 1 Schematic description of the serotonin pathway from enterochromaffin cells (ECs) to platelets and interactome regulation
through the membrane viscosity (depending from the regular arachidonic acid transfer from platelets to brain and vice versa) under
normal conditions.
Figure 2 Schematic hypothesis, in conditions of platelet membrane fatty acid modifications, of the serotonin pathway, from
enterochromaffin cells (ECs) to platelets, and regulation of the interactome through the membrane viscosity. When platelets reach a
very high concentration of arachidonic acid, exchanges of arachidonic acid between platelets and the brain and vice versa are not possible;
arachidonic acid increases in the brain and neurons, and platelet membranes become very fluid (loss of viscosity) impairing serotonin uptake in
both cells.
Cocchi et al. Annals of General Psychiatry 2011, 10:9
http://www.annals-general-psychiatry.com/content/10/1/9
Page 3 of 7
The results reported in the literature with regard to the
involvement in osteoporosis of brain or intestinal seroto-
nin, as well as its action on osteoclasts and osteoblasts,
are conflicting. Rosen [26], citing Yadav’s work [27],
reports that intestinal serotonin inhibits bone formation
independently from the activity of brain serotonin. In
subsequent work, Yadav [28] reports that the influence of
brain serotonin on bone mass takes precedence over that
exerted by serotonin of intestinal origin. However, the
same work emphasises how, according to the place of
synthesis, serotonin regulates bone mass in different
ways, inhibiting (duodenal serotonin) and favouring
(brain serotonin) by attributing such effects to the seroto-
nin condition of hormone or neurotransmitter.
The New England Journal of Medicine published a dis-
cussion about the article by Rosen [26]. Some authors
disagree with Rosen’s theory on the influence of seroto-
nin, together with its origin and mode of transport, in
the determination of the osteoporotic process.
Anderson et al. [29] stress the paradox that the
increase in platelet serotonin in Lrp5 gene knockout
rats and in subjects with osteoporosis pseudoglioma
leads to bone loss, whereas treatment with selective ser-
otonin reuptake inhibitors (SSRIs), which reduce platelet
serotonin by about 80% to 95% is also responsible for
the reduction of bone mass.
If serotonin apparently inhibits bone formation, it is
puzzling that carcinoid syndrome is not commonly asso-
ciated with osteoporosis.
de Jong et al. [30] emphasise that, after treatment with
SSRIs, free serotonin should be high (it seems that the
level of free serotonin after SSRI treatment is not known),
making this condition similar to serotonin-producing sub-
jects with metastatic carcinoid tumours, with the caveat
that these subjects do not have any particular tendency to
osteoporosis.
de Jong et al. [30] provide a possible explanation for
the discrepancy, with regard to the metabolic clearance
of serotonin.
Since SSRIs also reduce serotonin clearance in
peripheral transporter-expressing target organs, such as
bone, serotonin receptor activation is increased. In con-
trast, in patients with carcinoid tumours, transporter
function is intact and metabolic clearance can be highly
upregulated [31].
Rosen [32] makes observations stressing two main
aspects of the mechanisms that cause the osteoporotic
phenomenon. Firstly, with respect to the mechanism of
bone loss from sympathetic activity, activated adrenergic
receptors on osteoblasts suppress critical transcription
factors necessary for bone formation but also enhance
osteoclastogenesis, principally by upregulating the osteo-
clast differentiation factor receptor activator of nuclear
factor B ligand (RANKL) [33]. This is not a diversion of
osteoblasts to osteoclasts, as noted by Speth [34], but
rather a dynamic process of coupling that involves two
cell types originating from distinct progenitor cells. Sec-
ondly, the mechanism of bone loss induced by SSRIs.
[27]. Hence, it is conceivable that there is a balance in
bone turnover between the central blockade of serotonin
reuptake and changes that may be associated with circu-
lating serotonin and its release from platelets.
Karsenty [35] states that inhibition of the serotonin of
intestinal origin is an effective solution in the treatment
of osteoporosis, and Battaglino et al. [36] state that
experimental data suggest that serotonin plays a key
role in bone homeostasis through an effect on osteo-
clasts differentiation. Regardless, there is unanimity of
views, from the same authors, on the role of SSRIs in
the osteoporotic process.
Depression and osteoporosis
In this maze of conflicting evidences, on the basis of the
strong probability that circulating serotonin can be
invoked in osteoporosis and, further, for the possible liabi-
lity of the SSRIs in the induction of the osteoporotic phe-
nomenon, we consider the hypothesis that derives from
research conducted on the relationship between mem-
brane viscosity and serotonin plausible with regard to the
possible role of osteoporosis in depression [10-15]. Aware-
ness of a strong link between depression and osteoporosis
[25] is growing, although a clear definition of the connec-
tion between the two diseases is not yet available.
On the basis of the research conducted on the role of
platelets and their membrane fatty acids [37] it has been
shown that the viscosity could be a focus of attention in
order to allow a new interpretation of the serotonin
receptor uptake [11,12] and of the relationship between
depression, osteoporosis, and other diseases in which
serotonin is involved with respect to possible anomalies
in cell (platelet and neuron) concentration (Figure 3).
The above reasons make plausible, from a different
point of view, that the involvement of depressive disor-
ders on the osteoporotic phenomenon, as if to mimic
SSRIs activity in their phase of initial platelet receptors
reuptake inhibition, can cause a significant reduction of
serotonin (see Figures 1 and 2).
In the sequence of the molecular events that can lead
to fluctuation in the viscosity of the platelet membrane,
namely the phenomenon of exchange of arachidonic
acid from platelets and brain and vice versa, we have
shown that when platelets are saturated with arachido-
nic acid this exchange is no longer possible [13,14] and
the two areas of serotonin receptors (platelets and
neurons) could have limitations of serotonin reuptake
for the reduction of viscosity [15], freeing serotonin.
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An excess of serotonin, as suggested by Rosen and
comparing the two theories, probably complementary,
may lead to an insult to the bone.
The activity of SSRIs on the one hand, leads to a
reduction of depressive disorder by promoting the entry
of larger amounts of serotonin in the brain on the other
hand, continuing the inhibiting effect of the serotonin
uptake on the platelet membrane receptors [38]. This,
essentially leaves the serotonin decoupled from platelet
receptors and could maintain the osteoporotic effect. In
short, even during depression treatment, platelet mem-
brane viscosity does not change, and it would remain a
permanent stimulus to the impairment of bone homeos-
tasis and of other diseases that have serotonin inbalance
as a common feature.
Conclusions
At the time it is shown that the viscosity of the platelet
membrane is a general influencing factor for serotonin
receptor uptake, a general principle governing the handling
of serotonin itself is established with regard to its relations
with the depressive disorder. It may also be involved, to a
certain extent, in some pathologies that recognise serotonin
changes; that is, scleroderma, inflammatory bowel disease,
neuroinflammation, multiple sclerosis and osteoporosis.
The high incidence of depression, in these pathological
conditions, leads us to consider a general phenomenologi-
cal rule rather than a specific error in gene expression or
loss of enzyme function. The viscosity of the membrane
appears to be a concept more plausible than the fact that
it is a phenomenon to which changes may contribute
more general factors compared to the exclusivity of a gene
expression error and/or an abnormality of enzyme func-
tion. The serotonin receptors and their subtypes, together
with the modification of gene expression of transporters,
represent a very complex and intriguing network. We
must understand if it is possible to find a general and
common rule to explain all the different molecular aspects
of the serotonin pathways, tissue connections and respon-
sibilities in its involvement in pathologies.
The platelet molecular error identified in depression
[9,11] seems to not be irreversible in all subjects, but
could, in some cases, be partially recoverable by correc-
tion of membrane viscosity.
This refers to the portion of the population that may
experience mood disorders of varying intensity where
there is defective membrane dependent transport of ser-
otonin, which could also affect correct osteblastogenesis.
The concept of membrane viscosity [11] and the
implications that are reflected on the molecular home-
ostasis of the cytoskeleton, can be the link to which
future research to better understand the complex phe-
nomenon should be directed at, which bidirectionally
links the brain-gut axis in relation to serotonin trans-
port, and that likely makes the depressive condition the
disorder to which other diseases may be related.
Figure 3 The possible links between depression and other pathologies where serotonin is involved, according to the hypothesis of
compromised serotonin transport. The compromised serotonin transport, which depends on membrane viscosity, can cause conditions of
increased or decreased serotonin uptake by platelets leading to altered platelet function that in turn could be involved in different pathologies.
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In depression, the evidence of a reduced uptake of ser-
otonin in platelets and neurons, justifies the possible
influence of free serotonin on bone mass regardless of
origin, brain or blood.
In conclusion, depression, is a logical correspondence
between biological markers and biolocial-cultural
expressions, considered as the essential interpretation
key of human existence, from the biological point of
view, as well as from a symbolic-cultural and existential
perspective, according to Figure 4.
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